Evaxion Biotech Pseudomonas Aeruginosa Vaccine Patent

Tue, 21 Apr 2026 12:42:56 +0000
Intellectual Property

The USPTO granted patent US12606597B2 to Evaxion Biotech A/S on April 21, 2026. The patent covers immunogenic proteins from Pseudomonas aeruginosa as well as nucleic acids, vectors, and transformed cells useful for expression of the proteins, along with methods for prophylaxis of infection. The patent contains 12 claims.